KR20060088090A - Health functional egg affording the high density lipoprotein in human body - Google Patents
Health functional egg affording the high density lipoprotein in human body Download PDFInfo
- Publication number
- KR20060088090A KR20060088090A KR1020060062616A KR20060062616A KR20060088090A KR 20060088090 A KR20060088090 A KR 20060088090A KR 1020060062616 A KR1020060062616 A KR 1020060062616A KR 20060062616 A KR20060062616 A KR 20060062616A KR 20060088090 A KR20060088090 A KR 20060088090A
- Authority
- KR
- South Korea
- Prior art keywords
- cholesterol
- silver nano
- inorganic salts
- weight
- human body
- Prior art date
Links
- 102000015779 HDL Lipoproteins Human genes 0.000 title description 13
- 108010010234 HDL Lipoproteins Proteins 0.000 title description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 138
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 66
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229910052709 silver Inorganic materials 0.000 claims abstract description 32
- 239000004332 silver Substances 0.000 claims abstract description 32
- 241000287828 Gallus gallus Species 0.000 claims abstract description 21
- 229910017053 inorganic salt Inorganic materials 0.000 claims abstract description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 40
- 244000144977 poultry Species 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 235000000346 sugar Nutrition 0.000 claims description 14
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 229940088710 antibiotic agent Drugs 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 7
- 235000011152 sodium sulphate Nutrition 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical group [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- 235000011148 calcium chloride Nutrition 0.000 claims description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 6
- 235000011147 magnesium chloride Nutrition 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000007740 vapor deposition Methods 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 abstract description 45
- 235000013330 chicken meat Nutrition 0.000 abstract description 20
- 210000002969 egg yolk Anatomy 0.000 abstract description 11
- 102000002322 Egg Proteins Human genes 0.000 abstract description 10
- 108010000912 Egg Proteins Proteins 0.000 abstract description 10
- 230000009931 harmful effect Effects 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 9
- 235000013345 egg yolk Nutrition 0.000 abstract description 9
- 241000894006 Bacteria Species 0.000 abstract description 8
- 230000004060 metabolic process Effects 0.000 abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 238000009826 distribution Methods 0.000 abstract description 2
- -1 feed Chemical compound 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 16
- 235000013594 poultry meat Nutrition 0.000 description 15
- 235000013339 cereals Nutrition 0.000 description 13
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 7
- 235000010445 lecithin Nutrition 0.000 description 7
- 229940067606 lecithin Drugs 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 6
- 238000008214 LDL Cholesterol Methods 0.000 description 5
- 238000000151 deposition Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XIIAYQZJNBULGD-UHFFFAOYSA-N (5alpha)-cholestane Natural products C1CC2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XIIAYQZJNBULGD-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091007403 Cholesterol transporters Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930014097 furanoid Natural products 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000005240 physical vapour deposition Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L15/00—Egg products; Preparation or treatment thereof
- A23L15/30—Addition of substances other than those covered by A23L15/20 – A23L15/25
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
본 발명은 닭 사료에 사용되는 소금 등의 무기염류를 은나노 무기염류로 대체함으로서 닭 체내 흡수, 대사, 분포 등을 원활히 하고 은나노 항균활성으로 닭 체내의 각종 세균의 성장을 억제하여 신진대사를 증진시켜 체내에 유해한 물질을 쉽게 배출함으로서 닭이 생산하는 계란의 건강 기능성을 증진시켜 계란 난황에 포함된 콜레스테롤이 인체에 섭취시 인체에 유익한 HDL 콜레스테롤 함량을 증가시키는 기능성 계란을 제공한다. The present invention replaces inorganic salts such as salts used in chicken feed with silver nano inorganic salts to facilitate the absorption, metabolism and distribution of the chicken body and inhibit the growth of various bacteria in the chicken body by silver nano antibacterial activity to promote metabolism By easily releasing harmful substances into the body, it enhances the health functional properties of eggs produced by chickens, thereby providing functional eggs that increase the content of HDL cholesterol beneficial to the human body when cholesterol contained in egg yolk is ingested in the human body.
계란, 난황, 고밀도, 콜레스테롤, 사료, 은나노, 무기염류, 항균활성 Egg, egg yolk, high density, cholesterol, feed, silver nano, inorganic salt, antibacterial activity
Description
본 발명은 인체 내 고밀도 콜레스테롤 함량을 증가시키는 건강 기능성 계란에 관한 것이다. 더욱 상세하게는 무기염류를 은나노 무기염류로 대체하고 항생제의 첨가량을 대폭 감소시킨 사료를 섭이시킨 닭이 생산하는 건강 기능성 계란에 관한 것으로, 상기 건강 기능성 계란 난황에 포함된 콜레스테롤이 인체에 섭취시 인체에 유익한 HDL 콜레스테롤 함량을 증가시키는 건강 기능성 계란에 관한 것이다.The present invention relates to a healthy functional egg that increases the high density cholesterol content in the human body. More specifically, the present invention relates to a healthy functional egg produced by a chicken fed an inorganic salt substitute with a silver nano inorganic salt and a feed which greatly reduced the amount of antibiotics. The cholesterol contained in the functional functional egg yolk is consumed by the human body. Relates to a healthy functional egg that increases the HDL cholesterol content beneficial.
콜레스테롤은 고등동물의 세포성분으로 널리 존재하는 스테로이드 화합물의 일종으로서 성장과 유지를 위해 필요한 모든 동물세포의 구성물질이고 생체 세포막의 물리적 상태를 조절해주며 스테로이드 호르몬, 비타민 D 및 담즙산의 전구체가 될 뿐만 아니라 뇌의 마이엘린 및 혈장 지단백질이 구성성분으로서 인체에 필수적 으로 요구되는 지질이다.Cholesterol is a kind of steroid compound widely found as a cellular component of higher animals. It is a component of all animal cells necessary for growth and maintenance, regulates the physical state of biological membranes, and is a precursor of steroid hormones, vitamin D and bile acids. In addition, myelin and plasma lipoproteins of the brain are essential lipids required by the human body.
상기와 같은 콜레스테롤은 인체 내에서 고밀도 콜레스테롤이라 불리는 고밀도 지단백(HDL : hign density lipoprotein) 또는 저밀도 콜레스테롤이라 불리는 저밀도 지단백(LDL : low density lipoprotein)의 형태로 혈액을 통해 운반되어 신진대사에 이용된다. 저밀도 지단백은 중요한 혈중 콜레스테롤 운송체이며, 콜레스테롤을 간에서 혈액으로 이동해 주기 때문에 혈액 내 유해한 콜레스테롤 함량을 높여주는 반면, 고밀도 지단백은 혈액 중의 콜레스테롤을 간으로 이동하여 콜레스테롤을 분해한 후 담즙을 통해 체외로 배설을 촉진해 주는 역할을 수행한다. 따라서 HDL 콜레스테롤은 많을수록 인체에 유익하며 반대로 LDL 콜레스테롤은 인체에 유해한 것으로 동맥경화를 유발하여 뇌혈관, 심혈관 질환을 유발시키는 것으로 알려지고 있다.Such cholesterol is transported through the blood in the form of high density lipoprotein (HDL) called low density cholesterol (LDL) or low density lipoprotein (LDL) called low density cholesterol in the human body is used for metabolism. Low-density lipoproteins are an important blood cholesterol transporter, and because they move cholesterol from the liver to the blood, it increases the content of harmful cholesterol in the blood, while high-density lipoproteins move cholesterol from the blood to the liver to break down cholesterol, and then into the body through bile. It plays a role in promoting excretion. Therefore, more HDL cholesterol is beneficial to the human body. On the contrary, it is known that LDL cholesterol is harmful to the human body, causing arteriosclerosis and causing cerebrovascular and cardiovascular diseases.
동맥경화, 비만, 고혈압, 협심증, 심근경색증, 뇌졸중 등의 각종 성인병을 예방하기 위해 콜레스테롤 함량을 저하시키려는 연구가 다양하게 진행되고 있고, 축산가에서는 한약재, 항생제, 바이오 세라믹 조성물 등 다양한 첨가물을 투입하여 육질을 개선하고 저콜레스테롤의 육제품을 생산하는 연구가 활발하게 이루어지고 있다. In order to prevent various adult diseases such as arteriosclerosis, obesity, hypertension, angina pectoris, myocardial infarction and stroke, various researches are being conducted to reduce cholesterol content, and livestock farmers put various additives such as herbal medicines, antibiotics and bio-ceramic compositions Research has been actively conducted to improve the quality of meat and produce low-cholesterol meat products.
대한민국 공개특허공보 제2004-27191호 '콜레스테롤이 감소된 알의 생산방 법'에서는 베타싸이클로덱스트린을 사료 또는 음용수 형태로 가금류에 급여하여 콜레스테롤이 감소된 알을 생산하는 방법을 개시하고 있다. 또한 대한민국 공개특허공보 제2006-11578호 '저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법'에서는 가금류용 콜레스테롤 저해제, 이를 포함하는 사료 및 사료 첨가제, 이를 이용한 저콜레스테롤 란의 생산방법을 개시하고 있다. 한편, 대한민국 특허 공개특허공보 제1998-16882호 '콜레스테롤 함량이 저하된 계란 생산용 닭 사료조성물 및 그 사료를 투여하여 생산된 계란'에서는 콜레스테롤 함량이 낮은 계란을 생산하기 위해 은행잎, 괴화 및 쇠뜨기 중에서 선택된 1종 이상의 푸라보노이드 함유 식물을 포함한 닭 사료조성물 및 그 사료조성물을 투여하여 콜레스테롤 함량이 저하된 계란을 생산하는 방법 및 이 방법에 의해 생산된 계란을 개시하고 있다.Korean Laid-Open Patent Publication No. 2004-27191 discloses a method for producing cholesterol-reduced eggs by feeding betacyclodextrin to poultry in the form of feed or drinking water. In addition, the Republic of Korea Patent Publication No. 2006-11578 'Poultry feed additives for producing low cholesterol and low cholesterol production method using the same in the poultry cholesterol inhibitors, feed and feed additives comprising the same, low cholesterol using the same Disclosed is a method of producing eggs. On the other hand, the Republic of Korea Patent Publication No. 1998-16882 'Chicken feed composition for egg production with reduced cholesterol content and eggs produced by administering the feed' in the ginkgo leaves, lumps and horsetail to produce eggs with low cholesterol content Disclosed are a chicken feed composition comprising one or more selected furanoid-containing plants, and a method for producing a low cholesterol content egg by administering the feed composition and eggs produced by the method.
그러나 콜레스테롤은 인체에 필수적으로 요구되는 성분으로 단순히 콜레스테롤 저하 식품을 제조하는 것만으로는 건강 기능성을 부여할 수 없는 것이고, 인체에 유해한 LDL 콜레스테롤의 함량을 저하시키고 인체에 유익한 HDL 콜레스테롤의 함량을 증진시키는 새로운 과제가 요구되는 것이다. However, cholesterol is an essential ingredient for the human body, and simply manufacturing cholesterol-lowering foods cannot impart health functionalities, and lowers the content of LDL cholesterol harmful to the human body and promotes the content of HDL cholesterol, which is beneficial to the human body. New challenges are required.
본 발명에서 이루고자 하는 기술적 과제는 닭 사료에 사용되는 소금 등의 무 기염류를 은나노 무기염류로 대체함으로서 닭 체내 흡수, 대사, 분포 등을 원활히 하고 은나노 항균활성으로 닭 체내의 각종 세균의 성장을 억제하여 신진대사를 증진시켜 체내에 유해한 물질을 쉽게 배출함으로서 닭이 생산하는 계란의 건강 기능성을 증진시켜 계란 난황에 포함된 콜레스테롤이 인체에 섭취시 인체에 유익한 HDL 콜레스테롤 함량을 증가시키는 기능성 계란을 개발하는 것이다.Technical problem to be achieved in the present invention is to replace the inorganic salts, such as salt used in chicken feed with silver nano inorganic salts to facilitate the absorption, metabolism, distribution, etc. in the chicken body and inhibit the growth of various bacteria in the chicken body by silver nano antibacterial activity By promoting the metabolism of the body by easily releasing harmful substances in the body to improve the health functional properties of the eggs produced by chickens to develop a functional egg that increases the HDL cholesterol content beneficial to the human body when the cholesterol contained in egg yolk will be.
본 발명의 목적은 당분, 단백질 등이 함유된 가금류용 곡물 100 중량부에 대해 은나노 코팅된 무기염류 0.01∼3 중량부, 항생제 0.001∼0.1 중량부를 포함하는 가금류용 사료 조성물을 급여시킨 닭이 생산하는 건강 기능성 계란에 있어서, 상기 건강 기능성 계란은 인체내 섭취시 혈중내 콜레스테롤의 함량을 고밀도 콜레스테롤(HDL) 함량이 전체 콜레스테롤 함량의 30 중량% 이상으로 상승시키는 건강 기능성 계란을 제공하는 것이다. An object of the present invention is to produce a chicken fed a feed composition for poultry containing 0.01 to 3 parts by weight of silver nano-coated inorganic salts, 0.001 to 0.1 parts by weight of antibiotics based on 100 parts by weight of poultry grains containing sugar, protein, etc. In the health functional egg, the health functional egg is to provide a health functional egg which raises the content of cholesterol in the blood to a high density cholesterol (HDL) content of more than 30% by weight of the total cholesterol content when ingested in the human body.
또한 상기 은나노 코팅된 무기염류는 염화나트륨, 염화칼슘, 염화칼륨, 염화마그네슘, 황산나트륨 등에서 선택된 1종 이상의 무기염류 1 중량부에 대해 0.01∼0.5 중량부의 은나노 화합물을 함유함을 특징으로 한다.In addition, the silver nano-coated inorganic salts are characterized by containing 0.01 to 0.5 parts by weight of the silver nano compound with respect to 1 part by weight of one or more inorganic salts selected from sodium chloride, calcium chloride, potassium chloride, magnesium chloride, sodium sulfate.
이때 상기 은나노 코팅된 무기염류는 입자크기 1∼50 nm의 은나노 입자를 무 기염류에 기상 증착시켜 제조됨을 특징으로 한다.In this case, the silver nano-coated inorganic salts are prepared by vapor-depositing silver nano particles having a particle size of 1 to 50 nm in inorganic salts.
이하 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에 사용되는 은나노 무기염류는 물리적 기상 증착법을 이용하여 진공 중에서 나노 크기의 99.99%의 은 입자들을 무기염류에 증착시키는 공법인 NAP(Nano Attached Powder) 제조공법을 사용하여 은나노 무기염류를 제조하였다. The silver nano inorganic salts used in the present invention were prepared by using a method of preparing NAP (Nano Attached Powder), which is a method of depositing 99.99% of the nano-sized silver particles in an inorganic salt under vacuum using physical vapor deposition.
NAP 제조공법으로 제조된 은나노 무기염류는 고순도(99.99%) 은나노 입자의 제조가 가능하고 나노 입자의 크기 조절이 용이하여 1∼50 nm의 은나노 입자를 정제 무기염류 위에 증착함으로서 나노 입자의 안정성이 뛰어난 것이 특징이다. 또한 무기염류에 증착된 순수한 은 50 ppm의 은나노 입자에 의해 살균 및 탈취 기능을 지닌다. The silver nano inorganic salts prepared by the NAP manufacturing method are capable of producing high purity (99.99%) silver nano particles and easily control the size of the nano particles, thereby depositing 1-50 nm silver nano particles on the refined inorganic salts to provide excellent stability of the nano particles. Is characteristic. In addition, it is sterilized and deodorized by pure silver particles of 50 ppm of silver deposited on inorganic salts.
이러한 은나노 무기염류가 사료로서 함유되어 닭에 섭취시키면 닭과 같은 가금류 속의 모든 해로운 균을 감소시키고 또한 장속의 유해균을 선택 살균하는 기능을 하여 신진대사를 증진시킨다. 또한 은은 부작용이 없고 섭취 후 3일 이내에 체외로 배출되고 생체의 건강한 세포를 활성화시켜서 가금류의 면역력을 높여주는 역할을 한다. 따라서 본 발명의 경우 은나노 무기염류를 사료에 혼합하여 닭에 급여함으로서 장내 유해균에 대한 살균력을 증진시키고 면역력을 증가시킬 뿐만 아 니라 닭이 생산하는 계란 난황 내의 콜레스테롤 및 레시틴의 적절한 조화를 유도하여 건강 기능성 향상된 계란을 생산하게 되는 것이다.When these silver nano inorganic salts are contained in the feed, the chickens reduce all harmful bacteria in poultry such as chickens, and also function to selectively sterilize harmful bacteria in the intestine, thereby enhancing metabolism. In addition, silver has no side effects and is released into the body within 3 days after ingestion, thereby activating healthy cells of the living body to increase the immunity of poultry. Therefore, in the case of the present invention, by feeding the silver nano inorganic salts in the feed to the chicken to increase the bactericidal power against the intestinal harmful bacteria and increase the immunity, as well as inducing the proper harmony of cholesterol and lecithin in egg yolk produced by the chicken health functional It will produce an improved egg.
한편, 사료에 투입된 항생제의 경우 2∼3주가 지나야 완전히 소화 배출되는데, 이러한 항생제가 완전히 소화 배출되기 전에 생산하는 계란의 경우, 닭 체내에 존재하는 잔여 항생제로 인하여 계란 내의 항생제 잔량을 유발하는 문제점이 제기되고 있다. 또한 항생제 남용에 의해 야기되는 계란 내의 항생제 내성을 지닌 세균의 증가는 내성을 함유한 유전 물질이 플라스미드의 접합이라는 전달에 의해 다른 세균으로 전이될 수 있으며, 이러한 항생제 내성 세균의 증가는 계란으로부터 인체에 전이될 수 있는 위험성을 갖고 있다. 이러한 이유로 인하여 최근에는 계란 내의 항생제 잔류를 엄격히 제한하고 있는 것이다. On the other hand, in the case of antibiotics put into the feed is completely digested and discharged after 2 to 3 weeks, the eggs produced before these antibiotics are completely digested, the problem of causing antibiotics in the eggs due to the residual antibiotics present in the chicken body Is being raised. In addition, the increase in antibiotic-resistant bacteria in eggs caused by antibiotic abuse can cause the genetic material containing resistance to be transferred to other bacteria by the transfer of a plasmid conjugation, which increases the resistance of bacteria from eggs to the human body. There is a risk of metastasis. For these reasons, antibiotic restrictions in eggs have recently been severely limited.
레시틴은 난황의 인지질 중 70∼80%에 해당하는 것으로 수용성 인산기와 지용성 지방산을 함유하고 있어 천연의 계면활성제로 통용되고 있는 것이다. 레시틴에는 지질을 분해하는 기능이 있으며, 담즙액에서 침전한 콜레스테롤을 흡수 분해하는 기능을 지니고 있다. 따라서 레시틴을 섭취하면 콜레스테롤 그 자체를 분해 흡수하여 콜레스테롤의 인체 축적을 예방할 수 있다. 그 외에도 레시틴은 불필요한 지방의 축적을 억제하는 역할을 하기 때문에 비만예방에 효과가 있고 유산이나 사산의 예방효과, 인슐린의 분비촉진에 대한 당뇨병 예방효과, 항암효과 등이 확인되고 있다.Lecithin corresponds to 70 to 80% of egg yolk phospholipids and contains water-soluble phosphate groups and fat-soluble fatty acids, which are commonly used as natural surfactants. Lecithin has the function of breaking down lipids and absorbing and degrading cholesterol precipitated from bile. Therefore, ingesting lecithin can prevent the body's accumulation of cholesterol by breaking down and absorbing cholesterol itself. In addition, lecithin is effective in preventing obesity because it plays a role in suppressing the accumulation of unnecessary fat, preventive effects of miscarriage and stillbirth, diabetes prevention to promote insulin secretion, and anti-cancer effects.
본 발명에서 생산되는 건강 기능성 계란의 경우 이와 같은 난황 내의 레시틴의 작용으로 인해 난황 콜레스테롤이 인체내에 섭취되어도 인체에 유익한 고밀도 콜레스테롤 형태로 운반 저장되어 인체에 유익한 역할을 하게 되는 것이다. 즉, 레시틴이 콜레스테롤을 흡착시켜 대사시킴으로서 콜레스테롤의 인체내 침작을 예방할 수 있는 고밀도 콜레스테롤 형태로 운반 저장케 되는 것이다.In the case of the healthy functional egg produced in the present invention, the yolk cholesterol is transported and stored in the form of high density cholesterol which is beneficial to the human body due to the action of lecithin in the yolk, thereby playing a beneficial role for the human body. In other words, the lecithin is absorbed and metabolized cholesterol so that it is transported and stored in the form of high density cholesterol that can prevent the invasion of cholesterol in the human body.
이하 실시예를 통해 본 발명을 더욱 상세히 설명한다. 그러나 이러한 실시예들로 본 발명의 범위를 한정하는 것은 아니다.The present invention will be described in more detail with reference to the following examples. However, these examples do not limit the scope of the present invention.
(제조실시예 1) 은나노 무기염류 함유 사료 조성물의 제조Preparation Example 1 Preparation of Silver Nano Inorganic Salt-Containing Feed Composition
당분, 단백질 등이 함유된 가금류용 곡물 100 중량부에 대해 은나노 코팅된 무기염류 0.5 중량부, 항생제 0.01 중량부를 포함하는 가금류용 사료 조성물을 제조한다. 이때 당분 및 단백질 등이 함유된 곡물은 옥수수, 밀, 콩, 보리, 쌀겨 등에서 선택된 곡물을 적절한 당분과 단백질 및 지질이 함유되도록 조합시켜 제조한다. 또한 은나노 코팅된 무기염류는 염화나트륨, 염화칼슘, 염화칼륨, 염화마그네슘, 황산나트륨 등에서 선택된 1종 이상의 무기염류 1 중량부에 대해 0.1 중량부의 은나노 화합물을 함유한 것으로, 이때 상기 은나노 코팅된 무기염류는 입자크기 5∼30 nm의 은나노 입자를 무기염류에 기상 증착시켜 제조된 것이다. A poultry feed composition comprising 0.5 parts by weight of silver nano-coated inorganic salts and 0.01 parts by weight of antibiotics is prepared for 100 parts by weight of poultry grains containing sugar, protein, and the like. At this time, grains containing sugar and protein are prepared by combining grains selected from corn, wheat, soybeans, barley, rice bran, etc. to contain appropriate sugars, proteins and lipids. In addition, the silver nano-coated inorganic salts contain 0.1 parts by weight of silver nano compounds based on 1 part by weight of one or more inorganic salts selected from sodium chloride, calcium chloride, potassium chloride, magnesium chloride, sodium sulfate, etc., wherein the silver nano-coated inorganic salts have a particle size of 5 It is produced by vapor-depositing silver nanoparticles of -30 nm in inorganic salts.
(제조실시예 2) 은나노 무기염류 함유 사료 조성물의 제조Preparation Example 2 Preparation of Silver Nano Inorganic Salt-Containing Feed Composition
당분, 단백질 등이 함유된 가금류용 곡물 100 중량부에 대해 은나노 코팅된 무기염류 0.6 중량부, 항생제 0.015 중량부를 포함하는 가금류용 사료 조성물을 제조한다. 이때 당분 및 단백질 등이 함유된 곡물은 옥수수, 밀, 콩, 보리, 쌀겨 등에서 선택된 곡물을 적절한 당분과 단백질 및 지질이 함유되도록 조합시켜 제조한다. 또한 은나노 코팅된 무기염류는 염화나트륨, 염화칼슘, 염화칼륨, 염화마그네슘, 황산나트륨 등에서 선택된 1종 이상의 무기염류 1 중량부에 대해 0.15 중량부의 은나노 화합물을 함유한 것으로, 이때 상기 은나노 코팅된 무기염류는 입자크기 5∼30 nm의 은나노 입자를 무기염류에 기상 증착시켜 제조된 것이다. A poultry feed composition comprising 0.6 parts by weight of silver nano-coated inorganic salts and 0.015 parts by weight of antibiotics is prepared based on 100 parts by weight of poultry grains containing sugar, protein, and the like. At this time, grains containing sugar and protein are prepared by combining grains selected from corn, wheat, soybeans, barley, rice bran, etc. to contain appropriate sugars, proteins and lipids. In addition, the silver nano-coated inorganic salts contain 0.15 parts by weight of silver nano compounds with respect to 1 part by weight of one or more inorganic salts selected from sodium chloride, calcium chloride, potassium chloride, magnesium chloride, sodium sulfate, and the like. It is produced by vapor-depositing silver nanoparticles of -30 nm in inorganic salts.
(제조비교예 1) 무기염류 함유 사료 조성물의 제조Preparation Example 1 Preparation of Inorganic Salt-Containing Feed Composition
당분, 단백질 등이 함유된 가금류용 곡물 100 중량부에 대해 무기염류 0.5 중량부, 항생제 0.01 중량부를 포함하는 가금류용 사료 조성물을 제조한다. 이때 당분 및 단백질 등이 함유된 곡물은 옥수수, 밀, 콩, 보리, 쌀겨 등에서 선택된 곡물을 적절한 당분과 단백질 및 지질이 함유되도록 조합시켜 제조한다. 또한 무기염류는 염화나트륨, 염화칼슘, 염화칼륨, 염화마그네슘, 황산나트륨 등에서 선택된 것이다. A poultry feed composition comprising 0.5 parts by weight of inorganic salts and 0.01 parts by weight of antibiotics is prepared for 100 parts by weight of poultry grains containing sugar, protein and the like. At this time, grains containing sugar and protein are prepared by combining grains selected from corn, wheat, soybeans, barley, rice bran, etc. to contain appropriate sugars, proteins and lipids. In addition, the inorganic salts are selected from sodium chloride, calcium chloride, potassium chloride, magnesium chloride, sodium sulfate and the like.
(제조비교예 2) 항생제 함량이 증가된 사료 조성물의 제조Preparation Example 2 Preparation of Feed Composition with Increased Antibiotic Content
당분, 단백질 등이 함유된 가금류용 곡물 100 중량부에 대해 무기염류 0.5 중량부, 항생제 0.5 중량부를 포함하는 가금류용 사료 조성물을 제조한다. 이때 당분 및 단백질 등이 함유된 곡물은 옥수수, 밀, 콩, 보리, 쌀겨 등에서 선택된 곡물을 적절한 당분과 단백질 및 지질이 함유되도록 조합시켜 제조한다. 또한 무기염류는 염화나트륨, 염화칼슘, 염화칼륨, 염화마그네슘, 황산나트륨 등에서 선택된 것이다. A poultry feed composition comprising 0.5 parts by weight of inorganic salts and 0.5 parts by weight of antibiotics is prepared based on 100 parts by weight of poultry grains containing sugar, protein and the like. At this time, grains containing sugar and protein are prepared by combining grains selected from corn, wheat, soybeans, barley, rice bran, etc. to contain appropriate sugars, proteins and lipids. In addition, the inorganic salts are selected from sodium chloride, calcium chloride, potassium chloride, magnesium chloride, sodium sulfate and the like.
(실시예 1) 사료 섭취를 통한 계란의 생성Example 1 Generation of Eggs through Feed Intake
실험동물로는 50주령 산란계(ISA brown 레그혼) 50수를 대조군 10마리, 시험군 10마리씩 완전 임의 배치하였다. 실험동물 사육실의 실내온도는 25℃, 상대습도 50%, 명암 16L:8D 조건으로 조절하였다. 산란계는 산란율이 일정할 때까지 상기 제조실시예 1, 2 및 제조비교예 1, 2에서 제조된 사료를 물과 실험식이를 자유급식하여 6주간 사육하였다. 제조실시예 1에서 제조된 사료를 섭취시킨 시험군을 제1군이라 칭하고, 제조실시예 2에서 제조된 사료를 섭취시킨 시험군을 제2군이라 칭하고, 제조비교예 1에서 제조된 사료를 섭취시킨 시험군을 제3군이라 칭하고, 제조비교예 2에서 제조된 사료를 섭취시킨 시험군을 제4군이라 칭한다.As the experimental animals, 50 50-week-old laying hens (ISA brown leghorn) were completely randomly placed in 10 control groups and 10 test groups. Indoor temperature of the experimental animal breeding room was adjusted to 25 ℃, relative humidity 50%, contrast 16L: 8D conditions. Laying hens were fed for 6 weeks by free feeding of water and experimental diets prepared in Examples 1 and 2 and Comparative Examples 1 and 2 until the laying rate was constant. A test group ingesting the feed prepared in Preparation Example 1 is called a first group, and a test group ingesting the feed prepared in Preparation Example 2 is called a second group, and consumed the feed prepared in Preparation Example 1 This test group is called a third group, and the test group ingested the feed prepared in Preparation Example 2 is called a fourth group.
각각의 시험군으로부터 생성된 계란을 수득하여 하기 시험을 행하였다. The eggs produced from each test group were obtained and the following tests were conducted.
(실시예 2) 난황 내 콜레스테롤 분석Example 2 Cholesterol Analysis in Egg Yolk
상기 4개의 시험군에서 생산된 계란의 난황 내 콜레스테롤 분석을 다음과 같이 행하였다. Egg yolk cholesterol analysis of eggs produced in the four test groups was performed as follows.
난백으로부터 분리된 난황 2 g을 33% KOH 용액 0.6 ml, 에틸알코올(EtOH) 9.4 ml 및 내부표준(Internal standard) 5α-콜레스탄(5α-cholestan, Sigma C-8300) 1ml을 첨가하여 75℃에서 1시간 동안 반응시킨다. 이후 헥산 10 ml 및 증류수 5 ml를 넣고 혼합하여 방치한 후 상층액을 황산나트륨으로 탈수한 후 여과한 시험용액을 기체 크로마토그래피(Hewlett Packard 6890 Plus, USA)로 분석하였다. HP-INNOWax 컬럼(0.25 ㎛ × 30 m × 0.32 mm)을 사용한 기체 크로마토그래피의 주입구 및 검출구 온도는 330℃이고 운반 기체는 질소를 사용하였다. 콜레스테롤 함량의 분석결과는 표 1에 나타나 있다.2 g of egg yolk isolated from egg white was added at 0.6 ° C by adding 0.6 ml of 33% KOH solution, 9.4 ml of ethyl alcohol (EtOH) and 1 ml of internal standard 5α-cholestan (Sigma C-8300). React for 1 hour. Thereafter, 10 ml of hexane and 5 ml of distilled water were added to the mixture, and the mixture was left to stand. The supernatant was dehydrated with sodium sulfate, and the filtered test solution was analyzed by gas chromatography (Hewlett Packard 6890 Plus, USA). The inlet and detector temperatures of the gas chromatography using an HP-INNOWax column (0.25 μm × 30 m × 0.32 mm) were 330 ° C. and the carrier gas was nitrogen. Results of analysis of cholesterol content are shown in Table 1.
따라서 본 발명의 제조실시예에서 제조된 사료를 섭취시킨 제1군과 제2군의 콜레스테롤 함량은 본 발명의 제조비교예에서 제조된 사료를 섭취시킨 제3군 및 제4군의 콜레스테롤 함량보다는 낮은 수치를 나타내었으나 그 유의성을 인정할만한 콜레스테롤 함량의 차이는 인정할 수 없었다. 즉, 본 발명의 건강 기능성 계란의 경우 통상의 사료를 섭취시킨 닭이 생산하는 계란에 비해 유의성이 있는 콜레스테롤 함량의 저하를 나타내지는 않았다.Therefore, the cholesterol content of the first group and the second group ingesting the feed prepared in the preparation example of the present invention is lower than the cholesterol content of the third and fourth groups ingesting the feed prepared in the production comparison example of the present invention. Although the numbers were shown, the difference in cholesterol content could not be recognized. That is, the healthy functional eggs of the present invention did not show a significant decrease in cholesterol content as compared to the eggs produced by chickens fed a conventional feed.
그러나 다음 실시예를 통해 본 발명의 건강 기능성 계란을 섭취한 경우와 통상적인 사료를 섭취하여 생산된 계란을 섭취한 경우 인체 내에서 고밀도 콜레스테롤 함량의 변화 여부를 측정하였다.However, the following example was measured whether the change in the high-density cholesterol content in the human body when ingesting the healthy functional eggs of the present invention and the eggs produced by ingesting a conventional feed.
(실시예 3) 혈중 콜레스테롤 분석Example 3 Blood Cholesterol Analysis
건강한 20대 청년 40명을 선발하여 4개의 군으로 나누어 1개 군에 10명씩 시험 패널을 설정한 후 패널의 혈중 콜레스테롤 함량을 측정한다. 그 후 시험군 제1군에는 제조실시예 1에서 생성된 계란을 섭취시키고, 시험군 제2군에는 제조실시예 2에서 생성된 계란을 섭취시키고, 시험군 제3군에는 제조비교예 1에서 생성된 계란을 섭취시키고, 시험군 제4군에는 제조비교예 2에서 생성된 계란을 섭취시킨다. 상기 4개의 시험군의 패널 10명에게 하루 계란 5개씩 5일간 섭취시킨 후 6일째 되는 날 그 혈액 내의 콜레스테롤 함량의 변화를 측정한다. 혈액 내의 콜레스테롤 함량은 총 콜레스테롤 함량과 저밀도 콜레스테롤 함량 및 고밀도 콜레스테롤 함량으로 나누어 측정하였다. Forty healthy young people in their twenties were selected and divided into four groups. Ten test panels were set up in one group, and the blood cholesterol content of the panel was measured. After that, the eggs produced in Preparation Example 1 were taken into the test group 1 group, the eggs produced in Preparation Example 2 were taken into the test group 2 group, and produced in Preparation Example 1 in the test group 3 group. Ingested eggs are taken, and the fourth group is fed the eggs produced in Comparative Example 2. Ten panels of the four test groups were ingested five eggs daily for five days, and then the change in cholesterol content in the blood was measured on the sixth day. The cholesterol content in blood was measured by dividing total cholesterol content, low density cholesterol content and high density cholesterol content.
일반적으로 총 콜레스테롤 함량이 200 mg/dl 이하인 경우 건강한 정상치로 인정되며 저밀도 콜레스테롤 함량은 100 mg/dl 이하인 경우 건강한 정상치로 인정되고 고밀도 콜레스테롤 함량은 50 mg/dl 이상인 경우 건강한 정상치로 인정된다. Generally, when the total cholesterol content is 200 mg / dl or less, it is recognized as a healthy normal value, and when the low density cholesterol content is 100 mg / dl or less, it is regarded as a healthy normal value, and when the high density cholesterol content is 50 mg / dl or more, it is regarded as a healthy normal value.
표 2는 시험군 제1군 내지 제4군에서 생성된 4 종류의 계란을 각각 4개의 군의 패널 10명의 최초 혈중 콜레스테롤 함량과 계란 섭취후 6일째 콜레스테롤 함량을 측정한 데이터이다.Table 2 shows data for measuring the initial blood cholesterol content and the cholesterol content of the six eggs produced in the first to fourth groups of the test group and the sixth day after the ingestion of eggs.
표 2에 나타난 바와 같이 본 발명의 건강 기능성 계란을 섭취한 시험군의 경우 계란 섭취전에 비해 HDL 콜레스테롤 함량이 약 20∼25% 정도 증가하였으나 제조비교예에서 제조된 통상의 계란을 섭취한 시험군의 경우 단지 LDL 콜레스테롤 함량만이 증가하였고 HDL 콜레스테롤 함량은 유의적 변화를 나타내지 않았다.As shown in Table 2, in the test group ingesting the healthy functional egg of the present invention, the HDL cholesterol content was increased by about 20 to 25% compared to before the egg intake, Only LDL cholesterol content was increased and HDL cholesterol content was not significantly changed.
따라서 통상의 계란을 섭취한 시험군의 경우 총 콜레스테롤 함량과 LDL 콜레스테롤 함량만이 증가하였으므로 인체에 유해한 영향을 나타내는 것으로 판단된다. 그러나 본 발명의 계란을 섭취한 시험군의 경우 총 콜레스테롤 함량은 약간 증가하였으나 LDL 콜레스테롤 함량은 유의적 변화가 없었으며 HDL 콜레스테롤 함량은 약 20∼25% 증가하여 인체에 유익한 건강 기능성을 부여함을 입증한 것이다. Therefore, in the case of the test group ingested the normal egg, only the total cholesterol content and LDL cholesterol content increased, it is considered to have a harmful effect on the human body. However, the test group ingesting the egg of the present invention slightly increased the total cholesterol content, but there was no significant change in the LDL cholesterol content and the HDL cholesterol content increased by about 20-25%, which proved to provide beneficial health functionalities to the human body. It is.
본 발명의 효과는 닭 사료에 사용되는 소금 등의 무기염류를 은나노 무기염류로 대체함으로서 신진대사를 증진시켜 체내에 유해한 물질을 쉽게 배출함으로서 닭이 생산하는 계란의 건강 기능성을 증진시켜 계란 난황에 포함된 콜레스테롤이 인체에 섭취시 인체에 유익한 HDL 콜레스테롤 함량을 증가시키는 건강 기능성 계란을 제공하는 것이다.The effect of the present invention is to replace the inorganic salts, such as salts used in chicken feed with silver nano inorganic salts to promote metabolism to easily discharge harmful substances in the body to enhance the health functional properties of eggs produced by chickens in egg yolk It is to provide a healthy functional egg that increases the content of HDL cholesterol beneficial to the human body when the cholesterol is ingested in the human body.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060062616A KR100835885B1 (en) | 2006-07-04 | 2006-07-04 | Health functional egg affording the high density lipoprotein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060062616A KR100835885B1 (en) | 2006-07-04 | 2006-07-04 | Health functional egg affording the high density lipoprotein |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060088090A true KR20060088090A (en) | 2006-08-03 |
KR100835885B1 KR100835885B1 (en) | 2008-06-09 |
Family
ID=37176646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060062616A KR100835885B1 (en) | 2006-07-04 | 2006-07-04 | Health functional egg affording the high density lipoprotein |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100835885B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100817029B1 (en) * | 2007-03-08 | 2008-04-18 | 대한민국 | Development of gastric protected slilver nanoparticle and their manufacturing method |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101128951B1 (en) | 2009-07-29 | 2012-03-27 | 이문현 | Domestic fowls breeding with the mixture of feed and silver powder and the eggs laid therefrom |
KR102595215B1 (en) | 2021-01-14 | 2023-10-26 | 유일상 | Functional eggs and feed additives for producing the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000041791A (en) * | 1998-12-23 | 2000-07-15 | 임인철 | Preparation method of multi-function sub-feed for egg-laying chicken |
KR100490698B1 (en) * | 2003-06-27 | 2005-05-19 | 주식회사 이지바이오시스템 | Feed additives decreasing cholesterol and thereof egg or pork produced by the said feed additives |
JP4602005B2 (en) | 2004-06-24 | 2010-12-22 | 有限会社東セラ | Antibacterial and deodorant for livestock and poultry |
KR20060082155A (en) * | 2005-01-11 | 2006-07-18 | 주식회사 세진천기토 | Eco-feed additives containing chungito and photosynthetic bacteria |
EP1728438A1 (en) | 2005-06-01 | 2006-12-06 | NOLabs AB | Feedstuff |
KR100773758B1 (en) * | 2006-07-04 | 2007-11-09 | 주식회사 에스에프 | Feed composition containing mineral coated with nano silver |
-
2006
- 2006-07-04 KR KR1020060062616A patent/KR100835885B1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100817029B1 (en) * | 2007-03-08 | 2008-04-18 | 대한민국 | Development of gastric protected slilver nanoparticle and their manufacturing method |
Also Published As
Publication number | Publication date |
---|---|
KR100835885B1 (en) | 2008-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102960568B (en) | Special biological feed for laying hen | |
JP2010235616A (en) | Salt or complex of methyl donor with phytic acid or its derivative, and method for synthesis thereof | |
CA3119295C (en) | Dietary supplement compositions | |
Donma et al. | Beneficial effects of poultry meat consumption on cardiovascular health and the prevention of childhood obesity | |
CN114828648A (en) | Pet food compositions | |
KR100835885B1 (en) | Health functional egg affording the high density lipoprotein | |
KR101706598B1 (en) | Composition comprising water-soluble fructooligosaccharide calcium for preventing or treating bone disease and joint disease | |
TW200939975A (en) | Dietary compositions for promoting weight loss | |
JP5503125B2 (en) | Visceral fat accumulation inhibitor | |
US20060189566A1 (en) | Muscle building agent and preventive or remedy for muscle weakening | |
KR100773758B1 (en) | Feed composition containing mineral coated with nano silver | |
JP2003113089A (en) | Chitosan-containing formulation having action to inhibit lipid accumulation and reduce cholesterol and food and drink | |
JP2011012005A (en) | Hyperlipidemia-ameliorating agent | |
KR100985246B1 (en) | Chickens containing organic germanium in high concentration and their breeding process | |
JP2006298783A (en) | Immunostimulating composition | |
KR100745569B1 (en) | A feed containing a organic manganese and a organic zinc for duck, and it's breeding method | |
WO2009144977A1 (en) | Oral composition for hair growth | |
JP2001240544A (en) | Anti-obesity medicine and lipid metabolism-improving medicine | |
KR20230000701A (en) | Healthy eggs that increase HDL cholesterol content by improving the health function of eggs | |
JP7184805B2 (en) | Betaine for prevention of obesity | |
CN115038435A (en) | Composition for obesity inhibition | |
JP2021078397A (en) | Lipid decrease promoter | |
CN106955357B (en) | A kind of compound orlistat composite preparation and its application for pet weight-reducing | |
KR20090035682A (en) | Immunomodulating agent | |
JP2010528651A (en) | Means and methods for improving poultry weight gain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
E902 | Notification of reason for refusal | ||
B701 | Decision to grant | ||
N231 | Notification of change of applicant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130603 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140602 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150602 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160601 Year of fee payment: 9 |
|
LAPS | Lapse due to unpaid annual fee |